新华制药(000756.SZ)逆市急吐9.5% H股续吐逾2%
受惠人行重启逆回购操作金额达9,000亿人民币推动,沪指及深成分别由低位2,851及10,551,掉头续升0.5%及1.1%高收2,890及10,728。不过,上周跑赢科技板块、因新冠肺炎肆虐行业需求增及医药相关板块均回落,其中国产软件、人工智能、国产芯片、医疗器械、医药生物、免疫治疗、病毒防治、独家药品、中药、流感、体外诊断、传感器及口罩依次跌逾1%-6%。
相关AH股以医药板块表现最差,尤其新华制药(000756.SZ)曾跌停低见9.05元人民币,收9.1元,急吐9.5%;本港新华制药(00719.HK)失守20天线,最低见4.12元,现造4.1元,续吐2.4%,成交218万股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.